Literature DB >> 24820408

Valuing QALYs at the end of life.

Jose-Luis Pinto-Prades1, Fernando-Ignacio Sánchez-Martínez2, Belen Corbacho3, Rachel Baker4.   

Abstract

The possibility of weighting QALYs differently for different groups of patients has been a source of debate. Most recently, this debate has been extended to the relative value of QALYs at the end of life (EoL). The objective of this study is to provide evidence of societal preferences in relation to this topic. Three cross-sectional surveys were conducted amongst Spanish general population (n = 813). Survey 1 compared increases in life expectancy for EoL patients with health gains from temporary health problems. Survey 2 compared health gains for temporary health problems with quality of life gains at the EoL (palliative care). Survey 3 compared increases in life expectancy with quality of life gains, both for EoL patients. Preferences were elicited using Person Trade-Off (PTO) and Willingness to pay (WTP) techniques presenting two different durations of health benefit (6 and 18 months). Health benefits, measured in QALYs, were held constant in all comparisons. In survey 1 mean WTP was higher for life extending treatments than for temporary health problems and the majority of respondents prioritised life extension over temporary health problems in response to the PTO questions. In survey 2 mean WTP was higher for palliative care than for temporary health problems and 83% prioritized palliative care (for both durations) in the PTO questions. In survey 3 WTP values were higher for palliative care than for life extending treatments and more than 60% prioritized palliative care in the PTO questions. Our results suggest that QALYs gained from EoL treatments have a higher social value than QALYs gained from treatments for temporary health problems. Further, we found that people attach greater weight to improvements in quality of life than to life extension at the end of life.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  End of life; Life extension; Palliative care; Person trade-off; QALY weights; Spain; Willingness to pay

Mesh:

Year:  2014        PMID: 24820408     DOI: 10.1016/j.socscimed.2014.04.039

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  12 in total

1.  Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2017-08-12

2.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

3.  Cancer Drugs Fund 2.0: A Missed Opportunity?

Authors:  Christopher McCabe; Ash Paul; Greg Fell; Mike Paulden
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

4.  Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.

Authors:  Rachel Baker; Helen Mason; Neil McHugh; Cam Donaldson
Journal:  Soc Sci Med       Date:  2021-04-02       Impact factor: 4.634

Review 5.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

6.  Extending life for people with a terminal illness: a moral right and an expensive death? Exploring societal perspectives.

Authors:  Neil McHugh; Rachel M Baker; Helen Mason; Laura Williamson; Job van Exel; Rohan Deogaonkar; Marissa Collins; Cam Donaldson
Journal:  BMC Med Ethics       Date:  2015-03-07       Impact factor: 2.652

7.  Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.

Authors:  Khachapon Nimdet; Surachat Ngorsuraches
Journal:  BMJ Open       Date:  2015-10-05       Impact factor: 2.692

8.  New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year.

Authors:  Arthur E Attema; Marieke Krol; Job van Exel; Werner B F Brouwer
Journal:  Eur J Health Econ       Date:  2017-03-08

9.  Incorporating equity in economic evaluations: a multi-attribute equity state approach.

Authors:  Jeff Round; Mike Paulden
Journal:  Eur J Health Econ       Date:  2017-06-01

10.  Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints.

Authors:  Neil McHugh; Job van Exel; Helen Mason; Jon Godwin; Marissa Collins; Cam Donaldson; Rachel Baker
Journal:  Soc Sci Med       Date:  2017-12-16       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.